Treatment
Toripalimab clinical trials
We’re tracking 167 recruiting studies that include Toripalimab, each written for real people, not researchers, below.
Recruiting studies
- NCT06221670RecruitingPhase 2
Toripalimab after surgery for high-risk early lung cancer
This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06201065RecruitingPhase 3
Targeted therapy and immunotherapy for advanced liver cancer
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Guangzhou, GuangdongAges 18–75 - NCT06187597RecruitingPhase 2
Toripalimab after chemoradiation for older esophageal cancer
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
Guangzhou, GuangdongAges 70–85 - NCT06155383RecruitingPhase 2
Surgery and immunotherapy combo for stomach cancer
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06178159RecruitingPhase 2
New drug combo before surgery for HER2-positive breast cancer
This trial tests a new combination of drugs (DV plus pertuzumab, with or without toripalimab) given before surgery for HER2-positive breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06170489RecruitingPhase 3
Study of JS004 plus toripalimab for Hodgkin lymphoma
This study tests a new combination of two drugs (JS004 plus toripalimab) versus standard chemotherapy for people with Hodgkin lymphoma that no longer responds to PD-1/PD-L1 immunotherapy. The goal is to see if the new combination works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07508761RecruitingPhase 1/Phase 2
IPG7236 with Toripalimab for advanced solid tumors
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
Shanghai, PuDongXinQuAges 18 years+ - NCT07584135RecruitingPhase 3
JS107, Toripalimab, and Chemotherapy for Advanced Stomach Cancer
This study tests a combination of three treatments—JS107, toripalimab (an immunotherapy), and chemotherapy—for advanced stomach cancer that has a specific protein marker called CLDN18.2. The goal is to see if this combination can shrink tumors and help patients live longer.
Guangzhou, GuangdongAges 18 years+ - NCT06117566RecruitingPhase 1/Phase 2
WX390 plus Toripalimab for advanced solid tumors
This trial tests a combination of two investigational drugs, WX390 and Toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Changchun, JilinAges 18 years+ - NCT06124963RecruitingPhase 2
WX390 plus Toripalimab for STK11-mutated cervical cancer
This trial tests a combination of an experimental pill (WX390) and an immunotherapy drug (Toripalimab) for a specific type of cervical cancer that has an STK11 gene change. It aims to see if this combination can shrink tumors or slow the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06127303RecruitingPhase 2
Toripalimab plus cryoablation for lung cancer with limited progression
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06079112RecruitingPhase 1/Phase 2
New drug combo for advanced bladder cancer
This trial is testing a new combination of two drugs—9MW2821 (a targeted therapy) and toripalimab (an immunotherapy)—for people with advanced bladder cancer. It aims to see if using them together can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT06020755RecruitingPhase 2
Toripalimab plus actinomycin-D for GTN with FIGO score 7
This trial tests a combination of two drugs — toripalimab (an immunotherapy) and actinomycin-D (chemotherapy) — as the first treatment for a specific type of pregnancy-related tumor (GTN) with a FIGO score of 7. The goal is to see if this combination works better than standard treatment.
Beijing, Beijing MunicipalityAges 18–60 - NCT06028672Recruiting
Immunotherapy plus chemotherapy for moderate-risk GTN
This trial tests a combination of an immunotherapy drug (toripalimab) and a chemotherapy drug (actinomycin-D) as the first treatment for gestational trophoblastic neoplasia (GTN) with a FIGO score of 5-6. It may help patients whose disease is at a moderate risk level.
Beijing, Beijing MunicipalityAges 18–60 - NCT05798845RecruitingPhase 2
Toripalimab plus radiation before surgery for stage II–IIIA lung cancer
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05729646RecruitingPhase 2
Pre-surgery chemotherapy with toripalimab for dMMR stomach cancer
This trial studies whether adding toripalimab (an immune therapy) to chemotherapy before and around surgery can improve outcomes for people with certain mismatch repair–deficient stomach cancers. It mainly targets tumors that are dMMR and not HER2-positive.
Hangzhou, ZhejiangAges 18–80 - NCT05342194RecruitingPhase 3
Testing an immunotherapy plus chemo for advanced bile duct cancer
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07706985RecruitingPhase 3
Immunotherapy for advanced nasopharyngeal cancer
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
Guangzhou, GuangdongAges 18–70 - NCT05302284RecruitingPhase 3
Testing RC48-ADC plus toripalimab for first-time urothelial cancer
This trial tests whether RC48-ADC combined with toripalimab works better as the first treatment for urothelial cancer that cannot be removed by surgery or has spread. It may help shrink tumors and improve outcomes in people whose cancer has the right HER2 and other eligibility features.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05147844RecruitingPhase 2
Toripalimab plus radiation for limited-spread nose cancer
This Phase 2 trial studies whether adding toripalimab (an immune therapy) to radiation can control nasopharyngeal cancer that has spread only to a few places. It may help by boosting the immune system while the radiation treats the tumor sites.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT04992559RecruitingPhase 2
Toripalimab after surgery and chemoradiation for head and neck cancer
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
Guangzhou, GuangdongAges 18–70 - NCT04891016RecruitingPhase 2
Immunotherapy with chemotherapy for locally advanced stomach cancer
This trial studies toripalimab (an immune system medicine) plus FLOT chemotherapy in people with stomach cancer that has grown locally but hasn’t spread to distant organs. It aims to improve control of the cancer and help more people have their tumors fully treated.
Zhengzhou, HenanAges 18–70 - NCT04861584RecruitingPhase 2
Immunotherapy plus chemo before bladder surgery for advanced cancer
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
Guangzhou, GuangdongAges 18–75 - NCT04778956RecruitingPhase 3
Toripalimab plus surgery vs surgery alone for recurring throat cancer
This trial tests whether adding toripalimab (an immune therapy) to surgery helps people with recurrent nasopharyngeal cancer live longer or control the cancer better than surgery alone. You may qualify if your recurrence can be fully removed by surgery and it came back after a certain amount of time.
Guangzhou, GuangdongAges 18–70
Common questions
- Are there clinical trials studying Toripalimab?
- Yes. Clin2 currently lists 167 recruiting studies that include Toripalimab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Toripalimab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Toripalimab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Toripalimab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.